Alkermes
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Alkermes sits in the top decile of US sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count).
Alkermes: 66 sponsored US clinical trials, 6 recruiting.
Alkermes sponsors 66 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 58 completed. 28 of these trials are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 7 trials.
Top-decile sponsor footprint
Alkermes ranks in the top decile of sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
58 of 60 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (96.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
66 total, page 1 of 2
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07540897
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
NCT06843590
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
NCT06358950
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
NCT05547100
Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder
NCT04987658
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
NCT03919994
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
NCT03610048
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
NCT03345979
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
NCT03201757
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
NCT03188185
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
NCT03187769
An Insulin Sensitivity Study in Healthy Subjects
NCT02922426
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02873208
A Phase 1 Safety Study in Adults With Schizophrenia
NCT02804568
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
NCT02696434
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
NCT02694328
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02669758
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
NCT02636842
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
NCT02634320
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
NCT02634346
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
NCT02537574
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
NCT02508506
A Water Consumption Study of ALKS 5461 in Healthy Volunteers
NCT02521857
A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers
NCT02545439
A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
NCT02479308
A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers
NCT02504463
Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
NCT02452801
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
NCT02413281
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
NCT02320032
A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers
NCT02272764
A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users
NCT02218021
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
NCT02218008
A Long-Term Safety Study of ALKS 5461
NCT02141399
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
NCT02158546
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
NCT02158533
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
NCT02161718
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
NCT02085135
A Study of ALKS 5461 in Healthy Volunteers
NCT02068105
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
NCT01895452
A Study of ALKS 3831 in Adults With Schizophrenia
NCT01903837
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
NCT01626456
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
NCT01493726
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
NCT01500200
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
NCT01469039
Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery
NCT01436032
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 14 |
| Phase 3 | 25 |
| Phase 4 | 3 |
What is open in the Alkermes pipeline
6 recruiting of 66 indexed (9% open); 58 completed (88%).
Phase mix: 28 late (III/IV) vs 36 early (I/II) (balanced across stages).
Top condition: Schizophrenia (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alkermes: open-pipeline peers nationwide
Peers matched on 66 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Alkermes sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 66 trials (± recruiting share)
- Cornell University · 66 trials · 15% recruiting
- New Mexico Cancer Research Alliance · 66 trials · 6% recruiting
- University of Kansas · 66 trials · 8% recruiting
- Prisma Health-Upstate · 67 trials · 9% recruiting
Sponsors near 9% open enrollment (± trial volume)
- DBV Technologies · 9% recruiting · 11 trials
- Florida Gulf Coast University · 9% recruiting · 11 trials
- Genfit · 9% recruiting · 11 trials
- HiberCell · 9% recruiting · 11 trials
Related
What to do with this Alkermes page
66 registered trials is a research-attention snapshot, not an endorsement of Alkermes or any single study.
- 6 of Alkermes's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Alkermes studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alkermes pipeline card: 66 registered trials from official public datasets.Report a data error.